Karuna is on a Mission
to develop first-in-class therapeutics that have the potential to dramatically improve life for people living with schizophrenia, Alzheimer’s disease, and pain, and their families.
Altering the Story of Serious Mental Illness
Our team has deep expertise in neuroscience and drug development and is committed to unlocking the potential of those living with debilitating diagnoses.
Learn More About Our Team
Compassion in Action
A Sanskrit word, karuna is any action taken to diminish the suffering of others.
We’re taking action to provide a more effective therapeutic option to the 21 million people worldwide affected by schizophrenia, as well as targeting Alzheimer’s and pain.
Learn More About this Unmet Need
Disrupting Psychosis, Activating Understanding
Karuna is developing novel therapies for psychiatric and neurological disorders.
Our lead product candidate, KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s.
Learn More About Our Programs
Newsroom
Get the latest from Karuna.